How Dominic Marasco's 25-Year Pharma Career Positions MannKind for Endocrine Market Growth

In early 2025, MannKind Corporation made a significant leadership move that signals the company’s confidence in its endocrine care strategy. Dominic Marasco, a seasoned pharmaceutical executive with more than two decades of commercial success across the industry, stepped into the role of President for the company’s Endocrine Business Unit. The appointment, effective January 6, 2025, represents MannKind’s efforts to bolster its executive ranks with proven talent as it prepares to scale operations around its flagship inhaled therapy platform.

Strategic Leadership Appointment: Why MannKind Brought in an Industry Veteran

The timing of Dominic Marasco’s arrival reflects a deliberate strategy. MannKind’s CEO Michael Castagna emphasized that the new leader’s global experience would be “instrumental” to the company’s future, particularly as positive clinical data for Afrezza—the company’s signature product—continues to accumulate. Rather than promoting internally, the company cast a wider net to recruit someone with experience navigating the complexities of bringing innovative therapies to market at scale.

This decision carries multiple implications. On one hand, it demonstrates confidence in the commercial opportunity ahead. On the other hand, some observers might interpret external recruitment as a sign that existing internal leadership structures required fresh perspective or additional firepower in the endocrine division.

From Amgen to MannKind: Dominic Marasco’s Path and Commercial Credentials

Dominic Marasco brings a resume that reads like a tour of biopharma’s most respected organizations. His career spans Amgen (where he led U.S. sales for the Neuroscience Business Unit and served as Global Commercial Head for the Biosimilars division), Eli Lilly, Sandoz Biopharmaceuticals, Quintiles Transnational Holdings, and most recently Syneos Health. Before joining MannKind, he held the position of Chief Commercial Officer at BioAgilytix Labs and served as Executive President and Chief Commercial Officer at Envision Pharma Group.

This trajectory demonstrates not just tenure, but progressive responsibility. Marasco has managed complex commercial operations across multiple therapeutic areas—from biosimilars to neuroscience to AI-driven pharma technology. His education reinforces his credibility: he’s a graduate of Philadelphia College of Pharmacy and completed Harvard Business School’s Advanced Management Program. For MannKind, these credentials signal that someone with battlefield experience in launching and scaling commercial programs now leads the endocrine division.

Afrezza’s Next Chapter: How New Leadership Could Accelerate Commercial Success

The real focus of this appointment centers on Afrezza, MannKind’s inhaled insulin therapy designed to improve diabetes management. The drug operates in an interesting niche—it delivers medication to the deep lung where it can either act locally or enter systemic circulation depending on therapeutic need. Unlike traditional insulin injections, Afrezza offers patients a non-needle alternative, though market adoption has historically been slower than some competitors.

Dominic Marasco’s background in commercial scaling and strategic growth suggests MannKind believes the product is ready for acceleration. His experience driving market penetration in crowded therapeutic spaces aligns with the challenge Afrezza faces: establishing itself in a diabetes market dominated by incumbent players. The appointment signals that MannKind is moving beyond proving efficacy to focusing on market capture and operational execution.

Institutional Investors React: Mixed Signals in MNKD Stock Activity

The market’s response to MannKind’s strategic initiatives has been nuanced. Institutional investor activity in Q3 2024 revealed both enthusiasm and caution. Major investors including Dimensional Fund Advisors, Federated Hermes, and Bank of America increased positions, with some funds more than doubling their stakes in the company. However, large positions were simultaneously being reduced—Millennium Management cut its holdings by over 65%, suggesting divergent views on the company’s trajectory.

Insider selling has also been notable. Between late 2024 and early 2025, MannKind executives and insiders sold approximately 396,740 shares combined, according to trading records. While insider selling doesn’t necessarily indicate problems, it reflects typical executive liquidity management. The pattern suggests that even as Dominic Marasco joined to drive commercial growth, some executives were diversifying personal portfolios.

What’s Next: Endocrine Care and the Broader Pipeline

MannKind’s focus extends beyond diabetes to include orphan lung diseases such as nontuberculous mycobacterial (NTM) lung infection, pulmonary fibrosis, and pulmonary hypertension. Dominic Marasco now oversees the endocrine-facing portion of this portfolio, while the company’s technology platform—dry-powder formulations and specialized inhalation devices—remains the competitive moat.

The appointment of an executive with his background suggests MannKind is preparing for a significant scaling phase. Whether Afrezza can achieve mainstream commercial success, and whether Dominic Marasco’s playbook from prior roles translates to this particular market, will ultimately determine whether this leadership move accelerates company growth or becomes a footnote in its history. For now, the market is watching closely to see how the new leadership navigates both opportunities and the inherent risks in bringing innovative therapies to patients who need them.